IN THE CLAIMS

Please amend the claims as follows:

Claim 1.(Currently Amended): An injectable aqueous solution preparation having a pH from 2 to 5, the preparation comprising water and ~~containing 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin, wherein the preparation comprises~~ the following components (A) and (B):

(A) 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin, and

(B) acetic acid and sodium acetate that render 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin soluble by itself at a pH of 2 to 5[[,]] ~~and the preparation is at a pH of 2 to 5~~.

Claim 2.(Currently Amended): The injectable aqueous solution preparation ~~containing 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin~~ according to claim 1, wherein

the preparation further comprises component (C):

(C) (i) cyclodextrin,

(ii) ascorbic acid and sodium ascorbate,

(iii) propylene glycol, or

(iv) at least one compound selected from the group consisting of sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and α-thioglycerin.

Claim 3. (Cancelled)

Claim 4. (Currently Amended): The injectable aqueous solution preparation ~~containing 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin~~ according to claim 1 or 2, wherein the aqueous solution preparation is an antitumor preparation.

Claim 5. (Cancelled)

Claim 6. (New): The injectable aqueous solution preparation according to claim 1, wherein the content of the component (B) is from 0.1 to 10% by weight in terms of acetic acid.

Claim 7 (New): The injectable aqueous solution preparation according to claim 1, wherein the content of acetic acid and sodium acetate in terms of acetic acid per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation is from 10 to 2000 mg.

Claim 8 (New): The injectable aqueous solution preparation according to claim 2, comprising the cyclodextrin (i).

Claim 9 (New): The injectable aqueous solution preparation according to claim 8, wherein the cyclodextrin (i) is an irreducible maltooligosaccharide comprising 6 to 12 glucose molecules which have been linked in a cycle by a α-1,4 glycosidic linkage.

Claim 10 (New): The injectable aqueous solution preparation according to claim 8, wherein the cyclodextrin (i) is at least one selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and derivatives thereof, wherein the

cyclodextrin derivatives are selected from the group consisting of maltosyl cyclodextrin, glucosyl cyclodextrin, dimethyl cyclodextrin, and hydroxypropyl cyclodextrin.

Claim 11 (New): The injectable aqueous solution preparation according to claim 8, wherein the content of the cyclodextrin (i) is from 1 to 20% by weight.

Claim 12 (New): The injectable aqueous solution preparation according to claim 8, wherein the content of the cyclodextrin (i) per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation is from 30 to 1000 mg.

Claim 13 (New): The injectable aqueous solution preparation according to claim 8, wherein the content of the component (B) is in terms of acetic acid is from 0.1 to 5.0% by weight.

Claim 14 (New): The injectable aqueous solution preparation according to claim 2, comprising the ascorbic acid and sodium ascorbate (ii).

Claim 15 (New): The injectable aqueous solution preparation according to claim 14, wherein the content of the ascorbic acid and the sodium ascorbate (ii) in terms of ascorbic acid is from 5 to 20% by weight.

Claim 16 (New): The injectable aqueous solution preparation according to claim 14, wherein the content of the acetic acid and the sodium acetate in terms of the acetic acid is from 0.5 to 8% by weight.

Claim 17 (New): The injectable aqueous solution preparation according to claim 14, wherein the acetic acid, the ascorbic acid, and their sodium salts are incorporated at the total content in terms of the respective acids from 0.1 to 20% by weight.

Claim 18 (New): The injectable aqueous solution preparation according to claim 14, wherein the acetic acid, ascorbic acid, and their sodium salts are incorporated at the total content in terms of the respective acids from 500 to 2000 mg per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 19 (New): The injectable aqueous solution preparation according to claim 2, comprising the propylene glycol (iii).

Claim 20 (New): The injectable aqueous solution preparation according to claim 19, wherein the content of the propylene glycol (iii) is from 40 to 70% by weight.

Claim 21 (New): The injectable aqueous solution preparation according to claim 19, wherein the propylene glycol (iii) is incorporated at the content from 1 to 4 g per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 22 (New): The injectable aqueous solution preparation according to claim 19, wherein the content of the component (B) in terms of acetic acid is from 0.5 to 8% by weight.

Claim 23 (New): The injectable aqueous solution preparation according to claim 2, comprising from 1 to 300 mg of the component (iv) per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 24 (New): The injectable aqueous solution preparation according to claim 1, comprising from 1 to 50 mg/mL of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 25 (New): The injectable aqueous solution preparation according to claim 1, which is an intravenous injectable aqueous solution preparation.